Alkermes plc (NASDAQ:ALKS) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lowered its holdings in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 93.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,801 shares of the company's stock after selling 140,081 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Alkermes were worth $282,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Venturi Wealth Management LLC purchased a new stake in shares of Alkermes in the 4th quarter worth $25,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Alkermes by 106.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock worth $47,000 after buying an additional 842 shares during the period. Blue Trust Inc. lifted its holdings in shares of Alkermes by 2,231.5% in the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company's stock worth $49,000 after buying an additional 1,629 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Alkermes by 558.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company's stock worth $85,000 after buying an additional 2,502 shares during the period. Finally, Cornerstone Investment Partners LLC purchased a new stake in shares of Alkermes in the 4th quarter worth $203,000. Hedge funds and other institutional investors own 95.21% of the company's stock.

Alkermes Trading Up 0.7%

Shares of Alkermes stock traded up $0.21 on Friday, hitting $31.42. The stock had a trading volume of 992,676 shares, compared to its average volume of 1,765,523. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45. The stock has a market cap of $5.18 billion, a price-to-earnings ratio of 14.48, a P/E/G ratio of 2.20 and a beta of 0.51. The company's 50 day moving average price is $30.56 and its 200 day moving average price is $30.74.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.19). Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The company had revenue of $306.51 million for the quarter, compared to analysts' expectations of $307.53 million. During the same period in the prior year, the company earned $0.43 earnings per share. The firm's revenue was down 12.6% on a year-over-year basis. Analysts predict that Alkermes plc will post 1.31 EPS for the current fiscal year.

Analyst Ratings Changes

ALKS has been the subject of several research reports. Royal Bank of Canada upped their target price on Alkermes from $39.00 to $40.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. Robert W. Baird raised their target price on Alkermes from $38.00 to $41.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. StockNews.com downgraded Alkermes from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 5th. The Goldman Sachs Group increased their price target on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, UBS Group reissued a "sector perform" rating on shares of Alkermes in a research note on Monday, April 28th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Alkermes has an average rating of "Moderate Buy" and an average price target of $38.33.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.